Sarepta Therapeutics (NASDAQ:SRPT) Given New $15.00 Price Target at Piper Sandler

Sarepta Therapeutics (NASDAQ:SRPT) had its price target boosted by Piper Sandler to $15.00 in a research report released on Tuesday morning,Benzinga reports. Piper Sandler currently has a neutral rating on the biotechnology company’s stock.

A number of other research firms have also recently issued reports on SRPT. Leerink Partnrs cut Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 18th. TD Cowen cut Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $24.00 price target for the company. in a report on Wednesday, June 18th. Mizuho reissued a “neutral” rating and set a $14.00 price target (down from $40.00) on shares of Sarepta Therapeutics in a report on Monday, July 21st. Citigroup started coverage on Sarepta Therapeutics in a report on Tuesday, July 22nd. They set a “sell” rating for the company. Finally, Guggenheim dropped their price target on Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Six research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $49.12.

Sarepta Therapeutics Stock Performance

SRPT opened at $15.83 on Tuesday. Sarepta Therapeutics has a 12-month low of $10.41 and a 12-month high of $146.38. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -5.88 and a beta of 0.45. The business has a 50 day moving average of $25.16 and a 200-day moving average of $62.52. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The business had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same period in the previous year, the business earned $0.73 earnings per share. The business’s quarterly revenue was up 80.2% on a year-over-year basis. On average, equities research analysts expect that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Capital International Investors increased its stake in shares of Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares during the last quarter. Farallon Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 11.1% in the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after purchasing an additional 285,100 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Sarepta Therapeutics by 27.9% in the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock valued at $168,907,000 after purchasing an additional 577,848 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of Sarepta Therapeutics by 2.1% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company’s stock valued at $127,512,000 after purchasing an additional 41,408 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company’s stock valued at $207,538,000 after purchasing an additional 9,999 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.